<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00557401</url>
  </required_header>
  <id_info>
    <org_study_id>XP-B-057</org_study_id>
    <nct_id>NCT00557401</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD</brief_title>
  <official_title>A Multi-Center Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Study of XP19986 in Subjects With Symptomatic Gastroesophageal Reflux Disease (GERD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indivior Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indivior Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate efficacy and safety of treatment with XP19986 Sustained Release (SR) Tablet
      compared to placebo in subjects with symptomatic GERD
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of heartburn events over the treatment period</measure>
    <time_frame>4-weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of regurgitation; severity of heartburn and regurgitation; sleep symptoms</measure>
    <time_frame>4-weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Gastroesophageal Reflux</condition>
  <arm_group>
    <arm_group_label>XP19986 SR3, 20 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XP19986, 20 mg QD for approximately 32 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XP19986 SR3, 40 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XP19986, 40 mg QD for approximately 32 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XP19986 SR3, 60 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XP19986, 60 mg QD for approximately 32 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XP19986 SR3, 30 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XP19986, 30 mg BID for approximately 32 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for approximately 32 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XP19986 SR3, 20 mg QD</intervention_name>
    <description>XP19986 Sustained Release (SR) 20 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.</description>
    <arm_group_label>XP19986 SR3, 20 mg QD</arm_group_label>
    <other_name>arbaclofen placarbil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XP19986 SR3, 40 mg QD</intervention_name>
    <description>XP19986 Sustained Release (SR) 40 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.</description>
    <arm_group_label>XP19986 SR3, 40 mg QD</arm_group_label>
    <other_name>arbaclofen placarbil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XP19986 SR3, 60 mg QD</intervention_name>
    <description>XP19986 Sustained Release (SR) 60 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.</description>
    <arm_group_label>XP19986 SR3, 60 mg QD</arm_group_label>
    <other_name>arbaclofen placarbil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XP19986 SR3, 30 mg BID</intervention_name>
    <description>XP19986 Sustained Release (SR) 30 mg tablet taken orally, twice daily (BID) for approximately 32 days with titration and taper periods.</description>
    <arm_group_label>XP19986 SR3, 30 mg BID</arm_group_label>
    <other_name>arbaclofen placarbil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet taken orally for approximately 32 days with titration and taper periods.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History and documentation of GERD diagnosed by a gastroenterologist, with symptoms
             (heartburn and/or regurgitation) on â‰¥ 3 days during the week prior to screening and
             prior to randomization

        Exclusion Criteria:

          -  Current or historical endoscopic evidence of erosive esophagitis LA Classification
             Grade B, C, or D
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay Huff, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>XenoPort, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MDS Pharma Services</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2007</study_first_submitted>
  <study_first_submitted_qc>November 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2007</study_first_posted>
  <disposition_first_submitted>September 8, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>September 8, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 10, 2010</disposition_first_posted>
  <last_update_submitted>September 9, 2016</last_update_submitted>
  <last_update_submitted_qc>September 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arbaclofen placarbil</mesh_term>
    <mesh_term>Baclofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

